Key Trends Influencing the Growth of the Next-Generation Antibody Therapeutics Market in 2025: Revolutionizing Antibody Therapeutics By Exploring Cutting-Edge Technologies And Breakthroughs In Next-Generation Solutions

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Next-Generation Antibody Therapeutics Market Through 2025?
The market size for next-generation antibody therapeutics has witnessed a sharp increase in the past few years. The market is projected to expand from $6.82 billion in 2024 to reach a value of $7.63 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.8%. The surge during the historical period can be credited to the success of monoclonal antibody, an increase in chronic disease prevalence, the authorization of antibody-drug conjugates, and the expansion of immunotherapy, gene therapy, and antibodies.

What's the Projected Size of the Global Next-Generation Antibody Therapeutics Market by 2029?
In the coming years, the market size for next-generation antibody therapeutics is projected to experience rapid expansion. By 2029, it is anticipated to grow to a worth of $11.52 billion with a compound annual growth rate (CAGR) of 10.9%. The anticipated growth during this forecast period can be linked to developments in biosimilars, bispecific antibodies, and nanobodies, as well as patient-centric strategies, immunomodulatory antibodies, and expanded use in autoimmune diseases and continuous manufacturing. Upcoming trends for this period include progress in antibody engineering, the use of digital technology in antibody design, industry partnerships, advancements in drug delivery systems, and the application of real-world evidence in antibody development.

View the full report here:
https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Top Growth Drivers in the Next-Generation Antibody Therapeutics Industry: What's Accelerating the Market?
The growth of the next-generation antibody therapeutics market is anticipated to be driven by the rising incidence of chronic diseases. Chronic ailments are conditions that last for a year or more, requiring ongoing medical treatment, limiting daily activities, or both. Next-generation antibody therapeutics offer treatment solutions for those with chronic diseases, providing more targeted care that can enhance patient outcomes. In January 2023, for example, the US-based National Library of Medicine, the National Center for Biotechnology Information (NCBI), predicted that the count of those aged 50 years or more suffering from at least one chronic disease will skyrocket by 99.5% by 2050, reaching 142.66 million. As such, the escalating prevalence of chronic diseases is fuelling the expansion of the next-generation antibody therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp

What Trends Will Shape the Next-Generation Antibody Therapeutics Market Through 2029 and Beyond?
A key trend emerging in the next-generation antibody therapeutics market is the increasing focus on technological innovation. Essential players in this space are concentrating their efforts on developing novel advancements like the proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. This effort aims at refining protein identification and characterization, which, in turn, leads to more targeted, efficacious treatments. Consequently, this innovation strives to enhance therapeutic profiles, minimize costs, and tackle complex illnesses more accurately. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is a technique that systematically arranges protein molecules for amplified examination and quantification. This boosts precision and sensitivity in protein detection, highly beneficial in research and diagnosis purposes. For instance, in January 2024, Infinity Bio, Inc., a biotech firm based in the US, introduced a next-generation antibody profiling platform that uses MIPSA technology for high-volume, cost-effective analysis of immune responses. The goal is to deepen our understanding of diseases and tailor treatment strategies more personally.

What Are the Main Segments in the Next-Generation Antibody Therapeutics Market?
The next-generation antibody therapeutics market covered in this report is segmented -

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types
2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas
3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:
1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies
2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies
3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies
4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types
5) By Other Types: Nanobodies, Engineered Antibodies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12678&type=smp

Which Top Companies are Driving Growth in the Next-Generation Antibody Therapeutics Market?
Major companies operating in the next-generation antibody therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.

Which Regions Will Dominate the Next-Generation Antibody Therapeutics Market Through 2029?
North America was the largest region in the next-generation antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12678

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.